Novel therapeutic targets in neurodegenerative diseases: lessons from amyotrophic lateral sclerosis.
Appel
Stanley H
SH
Department of Neurology, Methodist Neurological Institute, 6560 Fannin, Suite #802, Houston, TX 77030, USA. sappel@tmhs.org
Beers
David R
DR
Henkel
Jenny S
JS
Zhao
Weihua
W
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D017628:Microglia / Q000502:physiology; D009046:Motor Neurons / Q000473:pathology; D009419:Nerve Tissue Proteins / Q000378:metabolism; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000473:pathology; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D010084:Oxidation-Reduction; D017510:Protein Folding; D013482:Superoxide Dismutase / Q000235:genetics / Q000502:physiology; D000072105:Superoxide Dismutase-1
D009419:Nerve Tissue Proteins; D016376:Oligonucleotides, Antisense; C000606290:SOD1 protein, human; C000606291:Sod1 protein, mouse; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1